SANGAMO ANNOUNCES RESEARCH COLLABORATION AGREEMENT WITH PFIZER

Sangamo BioSciences has entered into a research collaboration with Pfizer in the field of enhanced protein production.

Under the terms of the agreement, Pfizer will fund research at Sangamo and Sangamo will provide its proprietary zinc finger DNA binding protein technology for Pfizer to assess its feasibility for use in mammalian cell-based protein pharmaceutical production.

Sangamo will generate novel cell lines and vector systems for enhanced protein production as well as novel technology for rapid and robust creation of new production cell lines. The financial terms of the agreement were not disclosed.